Logo image of CTSO

CYTOSORBENTS CORP (CTSO) Stock Fundamental Analysis

NASDAQ:CTSO - Nasdaq - US23283X2062 - Common Stock - Currency: USD

1.22  +0.13 (+11.93%)

Fundamental Rating

2

CTSO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CTSO have multiple concerns. While showing a medium growth rate, CTSO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTSO has reported negative net income.
CTSO had a negative operating cash flow in the past year.
In the past 5 years CTSO always reported negative net income.
CTSO had a negative operating cash flow in each of the past 5 years.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of CTSO (-31.19%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -108.92%, CTSO is doing worse than 64.71% of the companies in the same industry.
Industry RankSector Rank
ROA -31.19%
ROE -108.92%
ROIC N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

CTSO's Gross Margin of 71.70% is amongst the best of the industry. CTSO outperforms 82.89% of its industry peers.
In the last couple of years the Gross Margin of CTSO has remained more or less at the same level.
CTSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTSO has been increased compared to 1 year ago.
CTSO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CTSO has a worse debt to assets ratio.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CTSO has an Altman-Z score of -7.11. This is a bad value and indicates that CTSO is not financially healthy and even has some risk of bankruptcy.
CTSO has a Altman-Z score of -7.11. This is in the lower half of the industry: CTSO underperforms 74.33% of its industry peers.
A Debt/Equity ratio of 0.98 indicates that CTSO is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.98, CTSO is not doing good in the industry: 77.01% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Altman-Z -7.11
ROIC/WACCN/A
WACC9.23%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CTSO has a Current Ratio of 2.61. This indicates that CTSO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.61, CTSO is in line with its industry, outperforming 50.80% of the companies in the same industry.
A Quick Ratio of 2.30 indicates that CTSO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.30, CTSO is in line with its industry, outperforming 52.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.3
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.33% over the past year.
CTSO shows a decrease in Revenue. In the last year, the revenue decreased by -5.86%.
Measured over the past years, CTSO shows a small growth in Revenue. The Revenue has been growing by 7.36% on average per year.
EPS 1Y (TTM)53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
Revenue 1Y (TTM)-5.86%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%-10.82%

3.2 Future

Based on estimates for the next years, CTSO will show a very strong growth in Earnings Per Share. The EPS will grow by 24.57% on average per year.
Based on estimates for the next years, CTSO will show a very strong growth in Revenue. The Revenue will grow by 28.10% on average per year.
EPS Next Y37.37%
EPS Next 2Y29.53%
EPS Next 3Y24.57%
EPS Next 5YN/A
Revenue Next Year6.12%
Revenue Next 2Y12.76%
Revenue Next 3Y18.81%
Revenue Next 5Y28.1%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTSO. In the last year negative earnings were reported.
Also next year CTSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

CTSO's earnings are expected to grow with 24.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.53%
EPS Next 3Y24.57%

More info and screens

0

5. Dividend

5.1 Amount

CTSO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOSORBENTS CORP

NASDAQ:CTSO (6/16/2025, 8:00:01 PM)

1.22

+0.13 (+11.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners27.77%
Inst Owner Change10.33%
Ins Owners8.54%
Ins Owner Change4.35%
Market Cap76.38M
Analysts80
Price Target7.14 (485.25%)
Short Float %2.8%
Short Ratio14.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.37%
Min EPS beat(2)-116.73%
Max EPS beat(2)71.99%
EPS beat(4)3
Avg EPS beat(4)3.22%
Min EPS beat(4)-116.73%
Max EPS beat(4)71.99%
EPS beat(8)5
Avg EPS beat(8)-6.13%
EPS beat(12)6
Avg EPS beat(12)-11.91%
EPS beat(16)6
Avg EPS beat(16)-28.93%
Revenue beat(2)0
Avg Revenue beat(2)-8.09%
Min Revenue beat(2)-11.18%
Max Revenue beat(2)-5.01%
Revenue beat(4)1
Avg Revenue beat(4)-6.38%
Min Revenue beat(4)-11.18%
Max Revenue beat(4)0.24%
Revenue beat(8)1
Avg Revenue beat(8)-7.38%
Revenue beat(12)3
Avg Revenue beat(12)-5.99%
Revenue beat(16)4
Avg Revenue beat(16)-6.05%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.75%
Revenue NQ rev (1m)-2%
Revenue NQ rev (3m)-6.83%
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-4.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.21
P/FCF N/A
P/OCF N/A
P/B 5.25
P/tB 7.05
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.55
BVpS0.23
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.19%
ROE -108.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.7%
FCFM N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
F-Score4
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.66%
Cap/Sales 1.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.3
Altman-Z -7.11
F-Score4
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)278.83%
Cap/Depr(5y)335.47%
Cap/Sales(3y)7.84%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
EPS Next Y37.37%
EPS Next 2Y29.53%
EPS Next 3Y24.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.86%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%-10.82%
Revenue Next Year6.12%
Revenue Next 2Y12.76%
Revenue Next 3Y18.81%
Revenue Next 5Y28.1%
EBIT growth 1Y43.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.74%
OCF growth 3YN/A
OCF growth 5YN/A